A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
Launched by NOVARTIS · Sep 12, 2005
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Arterial hypertension without previous regular treatment
- • Urinary albumin excretion rate above 30 mg / 24h
- • 30-65 years old
- Exclusion Criteria:
- • Reno-vascular arterial hypertension
- • Therapy resistant edema
- • Chronic heart failure, angina pectoris
- • Diabetes mellitus
- • Other protocol-defined exclusion criteria may apply
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials